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Abstract:  24 
IgA is an important mucosal antibody that can neutralize mucosal pathogens by either preventing 25 
attachment to epithelia (immune exclusion) or alternatively inhibit intraepithelial replication following 26 
transcytosis by the polymeric immunoglobulin receptor (pIgR). Chlamydia trachomatis is a major 27 
human pathogen that initially targets the endocervical or urethral epithelium in women and men, 28 
respectively. As both tissues contain abundant SIgA we assessed the protection afforded by IgA 29 
targeting different chlamydial antigens expressed during the extra and intraepithelial stages of 30 
infection. We developed an in vitro model utilizing polarizing cells expressing the murine pIgR 31 
together with antigen-specific mouse IgA, and an in vivo model utilizing pIgR-/- mice. SIgA targeting 32 
the extraepithelial chlamydial antigen, the major outer membrane protein (MOMP), significantly 33 
reduced infection in vitro by 24 %  and in vivo by 44 %. Conversely, pIgR-mediated delivery of IgA 34 
targeting the intraepithelial inclusion membrane protein A (IncA) bound to the inclusion but did not 35 
reduce infection in vitro or in vivo. Similarly, intraepithelial IgA targeting the secreted protease 36 
Chlamydia protease-like activity factor (CPAF) also failed to reduce infection. Together, these data 37 
suggest the importance of pIgR-mediated delivery of IgA targeting extra but not intraepithelial 38 
chlamydial antigens for protection against a genital tract infection. 39 
40 
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Introduction: 41 
Urogenital chlamydial infections globally affect an estimated 106 million people annually [1]. Infection 42 
can cause tissue inflammation, scarring, decreased fertility and can lead to infertility. Infections are 43 
often asymptomatic (40-60% of males and 70-90% of females) facilitating continued spread 44 
throughout the community [2]. In addition to the high incidence of subclinical infections in males, risk 45 
of sexual transmission is also greatest from infected male to uninfected female, occurring in 46 
approximately 40% of encounters [3]. Whilst antibiotic intervention is widely accepted to eliminate 47 
infection, it can arrest the development of adaptive immunity limiting the appropriate responses to 48 
subsequent infections [4]. For these reasons, it is widely accepted that there is a requirement for a 49 
chlamydial vaccine [5-7]. 50 
Chlamydial vaccine research is focused primarily on protecting against the chlamydial burden and 51 
immunopathology associated with infections in females, and has identified a crucial role for CD4+ T 52 
cells secreting IFNγ and TNFα [7]. There is considerably less research devoted to developing a male 53 
vaccine [6, 8], despite males arguably being the reservoir of infection and susceptible to infertility[8]. 54 
Whilst a vaccine eliciting IFNγ and TNFα secretion in response to infection may prove efficacious in 55 
females, a similar response may be immunopathological in males [8]. The presence of Chlamydia-56 
specific CD4+ T cells in male mice is associated with greater clearance of infection [9], yet CD4+ T 57 
cells secreting large amounts of IFNγ and TNFα are also associated with breakdown of immune 58 
privilege in the testes leading to infertility [10]. This suggests that a vaccine aimed at eliciting a cell-59 
mediated response to defend against infection could facilitate the development of male infertility. 60 
Antibodies however play a non-essential but supportive role during a natural chlamydial infection [7] 61 
and considerably improve protection against infection following vaccination  [11]. Thus, antibodies 62 
may be a safer alternative to potentially damaging CD4+ T cell responses in the context of a male 63 
vaccine. 64 
The role for IgA in chlamydial infections is controversial. Naive IgA-/- female mice show no significant 65 
difference to wild type mice in their ability to resolve primary or secondary C. muridarum infections 66 
[12]. However, the concentration of IgA in the human endocervix inversely correlates with C. 67 
trachomatis burden [13], and males secrete significantly more SIgA in penile secretions during C. 68 
trachomatis infection indicating SIgA may play an important role in human infection and transmission 69 
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[14]. Passive immunization of mice with monoclonal anti-MOMP IgA can also significantly reduce the 70 
magnitude of an infection in female mice [15-16]. Similarly, protection against tissue burden conferred 71 
following immunization of male mice with MOMP was dependent on secretion of IgA [11]. Thus, the 72 
protective role of IgA depends on the titer, which can be greatly enhanced with immunization and the 73 
accessibility of the target antigen.  74 
The pIgR is an integral membrane protein responsible for mucosal transport of dimeric IgA produced 75 
locally by plasma cells in the lamina propria. The pIgR is basolaterally expressed on epithelial cells 76 
where it binds dimeric IgA around the joining chain, internalizes and traffics it to the apical surface (i.e. 77 
the lumen) where pIgR is proteolytically cleaved releasing secretory component covalently bound to 78 
IgA, termed SIgA. SIgA is the dominant immunoglobulin at most mucosal surfaces and plays 79 
important roles in immune tolerance, mucosal homeostasis, commensal symbiosis, and immunity. In 80 
addition to epithelial trafficking of IgA to the mucosal lumen, pIgR transcytosis of IgA can also bind 81 
and neutralize already internalized viruses [17-19].  82 
Chlamydia spp. are obligate intracellular bacteria with a biphasic lifecycle consisting of an infectious 83 
extracellular metabolically inert elementary body (EB), and an intracellular metabolically active and 84 
replicating reticulate body (RB) phase. The chlamydial EB is highly resistant to physical and 85 
environmental disruption, due primarily to highly cross-liked and disulfide-bonded membrane proteins, 86 
principally the major outer membrane protein (MOMP) [20]. Following attachment and endocytosis of 87 
the EB by the host cell, chlamydiae escape the normal endocytic pathway and differentiate within a 88 
parasitophorous vacuole, termed the inclusion. The inclusion allows the pathogen to replicate and 89 
absorb nutrients without being subjected to/attacked by innate intracellular defenses such as 90 
lysosomal fusion. Some chlamydial inclusion membrane proteins, including the inclusion membrane 91 
protein A (IncA), face the host cytoplasm and directly interact/interfere with host vesicle fusion [21]. 92 
Within the inclusion, replicating RBs also produce proteases, such as chlamydial protease activity 93 
factor (CPAF), some of which are secreted into the host cell cytoplasm and may interfere with host 94 
cell processes [22].  95 
Chlamydia spp. express a variety of IgA-accessible epitopes. Therefore, we addressed the potential 96 
of SIgA to prevent attachment to and infection of host cells by targeting extra-epithelial chlamydial 97 
antigens presented on the EB and the ability of SIgA raised against intraepithelial chlamydial antigens 98 
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expressed during the RB phase to internalize and neutralize an already established infection. To 99 
address these questions we chose three widely studied antigens representing the EB (e.g. MOMP), 100 
inclusion membrane (e.g. IncA), and secreted chlamydial proteases (e.g. CPAF) groups. To 101 
determine the role of pIgR and antigen-specific IgA in against intra and extraepitheilal chlamydial 102 
antigens, we developed and utilized an in vitro Transwell® model, and confirmed the results in vivo 103 
using pIgR-deficient mice. We demonstrate that pIgR-mediated delivery of IgA targeting 104 
extraepithelial (MOMP), but not intracellular (IncA, CPAF), can significantly reduce chlamydial 105 
infection. These findings confirm the important role of pIgR and SIgA in chlamydial infections, and 106 
have implications for subunit chlamydial vaccines.  107 
108 
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Methods: 109 
Ethics: 110 
All experiments were performed with approval from the university animal ethics committee (UAEC) of 111 
the Queensland University of Technology (QUT), (UAEC #0800000824).  112 
Mice: 113 
Adolescent (>6 weeks) male C57BL/6 mice were purchased from the Animal Resource Centre (Perth, 114 
Australia) and C57BL/6 pIgR -/- mice were provided by Odilia Wijburg (University of Melbourne, 115 
Melbourne, Australia). Mice were fed ad libitum with procedures performed under physical 116 
containment level 2 (PC2) conditions following NHMRC guidelines. 117 
Cell Lines 118 
C. muridarum (Weiss; ATCC VR-123) was propagated in McCoy-B fibroblasts (ATCC CRL-1696) and 119 
purified as previously described [23]. DMEM high glucose (Invitrogen; Melbourne, VIC, Aus) was 120 
supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 µg/mL gentamycin sulphate 121 
(Invitrogen), 100 µg/mL streptomycin sulphate (Sigma Aldrich; Castle Hill, NSW, Aus), and 2 mM L-122 
glutamine (Invitrogen) was used to grow cells unless otherwise stated. The human endometrial 123 
epithelial cell line HEC-1A (ATCC: HTB-112) and human colonic epithelium C2Bbe1 (ATCC: CRL-124 
2102) cells were purchased from the ATCC. C2Bbe1 cells had 10 µg/mL of human transferrin 125 
(Invitrogen) added to the growth medium. Human endometrial epithelial cells ECC-1 (ATCC: CRL-126 
2923) were a gift from Charles Wira (Dartmouth Medical College, Lebanon, USA).  Madin-Darby 127 
canine kindey epithelial cell subclone MDCK I (ATCC: CCL-34) were a gift from Russell Simmons 128 
(Queensland Health Scientific Services, Brisbane Australia), and subclone MDCK II cells (ATCC: 129 
CRL-2936) were a gift from Finn-Erik Johansen (University of Oslo, Oslo, Norway). Human bronchial 130 
epithelial cells BEAS-2B (ATCC: CRL-9609) were a gift from Phillip Hansboro (University of 131 
Newcastle, Newcastle, Australia) and were grown in RPMI 1640 (Invitrogen) supplemented as for 132 
DMEM. The GK1.5 (ATCC: TIB-207) hybridoma was a gift from Graham Le Gros (Malaghan Institute 133 
of Medical Research, Wellington, New Zealand) and was maintained in supplemented RPMI 1640. 134 
Vero E6 (ATCC: CRL-1586) green African monkey kidney epithelial cells were a gift from John 135 
Aaskov (Queensland University of Technology, Brisbane, Australia) and were grown in supplemented 136 
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RPMI 1640. All cells were grown in a humidified incubator at 37oC and 5% CO2. Cells were 137 
periodically determined as Mycoplasma spp. free by PCR.  138 
Transwell Culture 139 
Epithelial cells were seeded onto 0.4 µm pore Transwell® inserts (BD Falcon; North Ryde, NSW, Aus) 140 
at 105 cells/6.5 mm insert (24 well format). Media in the apical (200 µL) and basolateral (600 µL) 141 
chambers was changed every second day. Transepithelial electrical resistance (TEER) was 142 
monitored daily with an EVOM electrode (Millipore; Kilsyth, VIC, Aus). TEERs were determined with 143 
the formula; TEERs (ohms.cm2) = (resistance of test (Ω) – resistance of blank insert (Ω)) x surface 144 
area of insert (cm2). Expression of zona occludens 1 (ZO-1) was determined following 5 days of 145 
growth on transwells, followed by 24 h of C. muridarum infection. Cells were fixed with 100% MeOH, 146 
blocked with 5% FCS in PBST, and then stained with primary antibodies sheep-anti MOMP and 147 
rabbit-anti ZO-1 (N-terminal)(Invitrogen) for 1 h at room temperature. Inserts were then washed with 148 
PBS and then incubated with secondary antibodies donkey-anti sheep IgG-Alexa Fluor 488 149 
(Invitrogen), and goat-anti rabbit IgG-Alexa Fluor 647 (Invitrogen) for 1 h at room temperature. Cells 150 
were then incubated with DAPI for 20 minutes and mounted with Prolong Gold (Invitrogen) overnight. 151 
Cells were then imaged using an SP5 confocal microscope (Leica) 152 
Quantitative Real Time PCR 153 
BEAS-2B, C2Bbe1, ECC-1 and HEC-1A cells were grown in culture, lysed and mRNA extracted with 154 
Trizol (Invitrogen), and cDNA synthesized with First Strand cDNA Synthesis Kit (Invitrogen) as per the 155 
manufacturer’s instructions. Exon-spanning primers were designed from human mRNA sequences 156 
and Primer 3 software. Primers for the amplification of human pIgR (200 bp, forward: 5’-157 
TGGCGGTCTTCCCAGCCATC -3’; reverse: 5’-GCTGGAGACGTAGCCCTCCGT-3’) and GAPDH (69 158 
bp, forward: 5’-CCACCCATG GCAAATTCC-3’, reverse: 5’-TGGGATTTCCATTGATGACAA-3’) were 159 
synthesized by Sigma Aldrich. Transcription of pIgR and GAPDH was quantified by PCR performed 160 
using a rotorgene thermocycler (Qiagen, Doncaster, VIC, Australia) with the conditions; 35 cycles of 161 
denaturing at 95oC for 20 seconds, annealing at 60oC for 20 seconds, and amplification at 72oC for 20 162 
seconds. 163 
Recombinant Protein Production 164 
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Recombinant C. muridarum MOMP was a generous gift from Harlan Caldwell (Rocky Mountain Labs, 165 
Hamilton, MT, USA) and was expressed and purified as previously described [23]. Lyophilized control 166 
antigen OVA was purchased (Sigma Aldrich) and resuspended in PBS. Full-length recombinant C. 167 
muridarum IncA (NP_296774) and CPAF (NP_296627) were produced by amplifying full length 168 
coding sequences with primers; IncA (845bp: For with BamHI 5’- 169 
CGGGATCCATGACATCACCTACTCTAG  -3’, Rev with EcoRI 5’-170 
CCGGAATTCTTAGGCGGAAGAATCAG -3’), and CPAF (1806bp: For with BamHI 5’- 171 
CGGGATCCATGAAAATGAATAGGATTTTGCTACTGC -3’, Rev with KpnI 5’- 172 
CCGGTACCTTAAAAACTTCCATCCTCTGAGAGAATAATTACAC -3’). Hot start PCR was performed 173 
with conditions of 95oC for 2 min, addition of Pfu polymerase (Promega), then 35 cycles of 95oC for 1 174 
min, 60oC for 1 min, and 74oC for 5 min. Amplicons were purified using Purelink PCR purification 175 
columns (Invitrogen) and restriction digested with BamHI/EcoRI (IncA) or BamHI/KpnI (CPAF) for 1 h 176 
at 37oC. Digested amplicons were ligated using T4 DNA Ligase (Promega; Alexandria, NSW, Aus) 177 
into the N’ terminal his-tag vector pRSET-A (Invitrogen) previously restriction digested with 178 
corresponding restriction enzymes. Vectors were transformed into BL21 (DE3) pLysS E. coli 179 
(Invitrogen), grown to O.D.600nm= 0.4 in LB broth, and then induced with 0.5 µM IPTG for 3 h at 30oC. 180 
E.coli was lysed and His-tagged protein purified using Talon affinity resin (Clontech; Clayton, VIC, 181 
Aus) as per the manufacturers’ instructions. Proteins were eluted with 150 mM imidazole (Sigma 182 
Aldrich), dialysed into PBS and stored at -80oC.  183 
Immunization Schedule of Mice to Obtain Antigen-Specific IgA 184 
Mice were immunized intranasally with 20 µg of antigen and 0.5 µg of cholera toxin on days 0, 7, 14 185 
and 25. Mice were euthanized by overdose of sodium pentobarbitone on day 35 and blood collected 186 
via cardiac puncture.  187 
Purification of Murine Total IgA from Sera 188 
Sera from immunized groups (n =10) were pooled and poorly solubilizing proteins precipitated by slow 189 
addition of half the serum volume of saturated ammonium sulfate, bringing the final volume of 190 
ammonium sulfate to approximately 30%. The serum was incubated at 4oC on a rotating wheel for 6 191 
h. Weakly soluble proteins were precipitated by centrifugation at 4,000 x g for 30 min at 4oC. The 192 
supernatant was collected and half the initial volume of saturated ammonium sulfate was added to 193 
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bring the final concentration to 50%. The sera were incubated on a rotating wheel overnight at 4oC. Ig 194 
was precipitated at 4,000 x g for 30 min at 4oC. The supernatant was discarded, and the Ig 195 
resuspended in PBS to 10 times the initial volume of sera. Ig was pooled and depleted of IgG by 196 
passing over Protein G resin (Genscript; Piscataway, NJ, USA) and collecting the flow through. IgG-197 
depleted ammonium sulfate fractioned antibody was further purified with Mouse IgA Purification Resin 198 
Kit (# MIKA-FF Kit; Affliland SA, Ans-Liege, Belgium) as per manufacturer’s instructions. Briefly, Ig 199 
was diluted in15 mL PBS, and IgA precipitated with 35 mL of precipitation buffer (Affliand SA) for 15 200 
min at room temperature. Protein was allowed to rest at 4oC for 30 min, and then centrifuged at 4,000 201 
x g for 15 min. The supernatant was collected (containing IgG, IgD IgE and other highly soluble 202 
proteins), and the precipitate (containing polymeric IgA and IgM) was resuspended in 10 mL of 203 
Binding buffer (Affiland SA). The soluble IgA/IgM in binding buffer was run over an equilibrated Mouse 204 
IgA Resin bed by gravity flow, washed with PBS, and eluted using Elution Buffer (Affiland SA). Protein 205 
containing fractions were pooled and concentrated using a 30 kDa molecular weight cut-off centrifuge 206 
filter (Millipore). To confirm purification of IgA, eluates were separated on non-reducing/non-207 
denaturing SDS-PAGE, and western immunoblotting and was determined to be >90 % IgA with no 208 
detectable IgM or IgG by sandwich ELISA. A typical yield following purification was 3-4 mg of IgA per 209 
mL of pIgR-/- serum. Aliquoted IgA was stored at -80oC until required.  210 
Transfection and Evaluation of mpIgR Transfectants 211 
C2Bbe1 cells were transfected with a vector encoding murine pIgR with Lipofectamine 2000 212 
(Invitrogen) and Plus Reagent (Invitrogen) as per the manufacturer’s instructions. Briefly, 213 
Lipofectamine complexed with pcDNA3.1 murine pIgR (pcDNA_mpIgR) generously donated by Finn-214 
Erik Johansen (University of Oslo, Norway) was transfected into equilibrated C2Bbe1 cells, and 215 
positive cells selected for in DMEM  supplemented with 550 µg/mL of G418 (Invitrogen). This plasmid 216 
has previously been shown to express functional mouse pIgR in MDCK cells [24]. Transfected clones 217 
were obtained by limiting dilution for monoclonal cell populations. Clones were evaluated on their 218 
ability to bind mouse IgA by incubating them with pIgR-/- sera (which pools IgA), fixing with 100% 219 
methanol, probed with goat anti-mouse IgA-HRP (Southern Biotechnology), and detecting with DAB 220 
precipitation (Thermo Fisher Scientific; Scoresby, VIC, Aus) and counter stained with Mayer’s 221 
hematoxylin (Sigma Aldrich). Clone 1 of 8 was found to bind the most IgA and was used thereafter. 222 
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Male Immunization and Challenge 223 
Mice were housed for 1 week prior to the initial immunization and immunized on days 0, 14 and 25 via 224 
the intranasal (IN) route. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), 225 
placed on their backs, and received IN immunizations, in a total volume of 5 µL, 2.5 µL per nare. On 226 
days 0, 7 and 14, 20 µg of antigen and 0.5 µg of cholera toxin (CT) was administered IN, and on day 227 
25 mice received a boost of 50 µg of antigen, 1 µg of cholera toxin and 10 µg of CpG (5’-TCC ATG 228 
ACG TTC CTG ACG TT-3’)(Sigma Aldrich). Mice were depleted of CD4+ cells by IP injection of 200 229 
µg of GK1.5 two days prior to penile challenge, and received continuous depletion with IP injection of 230 
100 µg of GK1.5 every week until euthanasia. Mice were infected with 106 IFUs of C. muridarum 231 
(Weiss) in 5 µL via the penile urethra to ensure 100% of mice were infected, as previously described 232 
[25].  At sacrifice, cardiac blood was taken for ELISA, which was performed as previously described 233 
[23]. Caudal and lumbar lymph nodes and spleens were taken for flow cytometry as previously 234 
described [26]. The testes, bladder and penis were collected and homogenized in sucrose phosphate 235 
glutamate (219 mM sucrose, 10 mM sodium phosphate, 5 mM L-glutamine) on the lowest speed 236 
(5000 x rpm) with a 220V generator probe (OMNI International, Kennesaw, USA) for 10 s, and stored 237 
at -80oC until IFUs were determined by culture on McCoy cells for 24 h and quantified by fluorescence 238 
microscopy as described elsewhere [26].   239 
Statistical Analysis 240 
Statistical analysis of data was performed using Graphpad Prism version 5. Unpaired two-tailed 241 
Student’s t tests and one-way ANOVA with Tukey’s post hoc tests were performed where indicated. 242 
All mouse work was performed using 5 animals per group as it was determined to have >80% 243 
statistical power. Significance was determined as * = P < 0.05, ** = P < 0.01, *** = P < 0.001. Graphs 244 
with error bars represent the mean ± the standard error of the mean (S.E.M). 245 
246 
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Results: 247 
Purification of Antigen-Specific IgA 248 
The ability of IgA targeting extra- and intra-cellular chlamydial antigens to prevent infection or to 249 
neutralize an established infection, respectively, was determined by targeting three chlamydial 250 
proteins potentially accessible to IgA binding (Figure 1A). To obtain antigens from the extra- and 251 
intracellular stages of the chlamydial life cycle, recombinant MOMP, IncA and CPAF were produced 252 
and purified (Figure 1B-C). Purified CPAF contained the full length protein, as well as the cleaved 253 
6xHis tagged N’ terminal of CPAF, consistent with recombinant CPAF’s ability to be self-cleaved [27].  254 
Both IncA and CPAF contained 6xHis tags confirmed by western blot; and MOMP, IncA and CPAF 255 
were all recognized by sera from C. muridarum-infected female mice (not shown). To obtain a high 256 
yield of purified IgA we immunized pIgR-/- mice as IgA pools in their plasma [28]. Because the 257 
proteins Jacalin or staphylococcal superantigen-like protein 7 (SSL7) bind human IgA but not mouse 258 
IgA,[29] we used Affiland® mouse IgA purification resin to purify polyclonal mouse IgA from the sera 259 
of immunized mice. To ensure minimal IgG was co-purified, serum was first depleted of IgG with 260 
Protein G resin. IgG-depleted sera was bound to Affiland® resin and eluted and samples from various 261 
stages of purification were evaluated by western blot for IgA (Figure 1D). IgA was found to be bound 262 
to washed resin and in eluted fractions, with no detectable IgM or IgG in the elutions as determined by 263 
sandwich ELISA (not shown). To confirm IgA was dimeric and not monomeric, non-reduced and non-264 
denatured IgA and IgG were run on PAGE (Figure 1E). To confirm that purified IgA was able to bind 265 
its corresponding antigens, IgA was used to probe chlamydial antigen separated by western blot 266 
(Figure 1F). Together, these data demonstrate the Affiland® mouse IgA purification resin can be used 267 
to purify polyclonal antigen-specific IgA from immunized pIgR-/- mouse sera and that purified IgA 268 
retains antigen-binding specificity. 269 
Establishment of an in vitro Model to Access the Protection Afforded from Intra- and Extra 270 
cellular IgA in Chlamydial Infections 271 
To determine the neutralizing potential of IgA targeting intra- and extraepithelial chlamydial antigens, 272 
a Transwell model using polarized epithelial cells expressing murine pIgR (mpIgR) was utilized 273 
(Figure 2A). As we were unable to locate a mouse cell line that constitutively expresses mpIgR and 274 
forms tight cell-cell junctions (i.e. polarizes), we screened a variety of epithelial cell lines known to 275 
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polarize in a Transwell® model, determined their susceptibility to infection once polarized, and 276 
transfected them with  a plasmid constitutively expressing mpIgR. The TEER of the cell lines in 277 
Transwells was determined over one week and human HEC1A, ECC-1 and C2Bbe1 cells, as well as 278 
canine MDCK I cells were found to strongly polarize (Figure 2B). However, upon polarization only 279 
C2Bbe1 cells remained  susceptible to chlamydial infection (Figure 2C), consistent with other findings 280 
[30]. Expression of human pIgR mRNA was also determined by qRT-PCR in BEAS-2B, C2Bbe1, 281 
ECC-1 and HEC-1A cell lines with BEAS-2B and ECC-1 lacking expression, C2Bbe1 with a small 282 
amount (1.5 x 10-6 relative copies), and HEC-1A with the largest amount (9 x 10-4 relative copies) 283 
(Figure 2D). As C2Bbe1 cells strongly polarized, remained susceptible to infection, and had low 284 
expression of human pIgR, these were selected for transfection with mpIgR and used in subsequent 285 
experiments.  286 
Following transfection with pcDNA-mpIgR, antibiotic selection, and cloning, the ability of transfected 287 
C2Bbe1 clones to bind murine IgA was determined by immunocytochemistry (Figure 2E). In the 288 
presence of 1% pIgR -/- sera (high in IgA), C2Bbe1 cells bound a small amount of mIgA consistent 289 
with the weak binding of mouse IgA by hpIgR, but when transfected with mpIgR bound considerably 290 
more IgA. 291 
To determine if monolayer integrity was affected by chlamydial infection, electrical resistance, passive 292 
flux and tight junction protein expression was investigated. Following 24 hrs of infection TEERs were 293 
non-significantly reduced (P = 0.15) in infected cells when compared to uninfected cells (Figure 2F). 294 
Interestingly, passive transport of FITC-dextran (4 kDa) was slightly but significantly reduced (P = 295 
0.03) in C. muridarum infected C2Bbe1 cells (0.3 ± 0.4 µM/hr) compared to mock treated C2Bbe1 296 
cells (1.25 ± 0.3 µM/hr) (not shown). Additionally, tight junction protein zona occludens 1 (ZO-1) 297 
expression was observable following C. muridarum infection (Figure 2G). The ability of polarized 298 
C2Bbe1 cells to transcytose mouse IgA was also significantly greater following mpIgR transfection 299 
compared to untransfected WT C2Bbe1 cells (P < 0.05) (Figure 2H). Taken together, these data 300 
confirm that C2Bbe1 cells can be infected when polarized, remain polarized when infected, and 301 
following transfection with murine pIgR bind and traffic murine IgA from the basolateral to the luminal 302 
compartment.   303 
SIgA Specific for Extra but not Intraepithelial Chlamydial Antigens, Reduces Infection in vitro 304 
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Utilizing the purified antigen specific IgA and the in vitro Transwell cell model, we evaluated the ability 305 
of pIgR-transported SIgA to neutralize the extraepithelial chlamydial EB and intraepithelial replicating 306 
chlamydial RB. When anti-MOMP and control anti-OVA IgA was added to polarized cells basolaterally 307 
prior to addition of EBs to the apical chamber, only MOMP-IgA added to cells expressing mpIgR 308 
caused a significant reduction in apical infection (24%; P < 0.05) (Figure 3A). When IgA targeting the 309 
chlamydial inclusion membrane protein (IncA) or secreted protease (CPAF) was added to infected 310 
cells basolaterally, no significant protection was afforded relative to OVA-IgA controls, regardless of 311 
pIgR expression (Figure 3B). There was also no significant reduction in viability of replicating C. 312 
muridarum in subsequent infections (not shown). To confirm that IgA in the process of transcytosis 313 
could interact with the chlamydial inclusion, confocal microscopy was also performed (Figure 3C). IgA 314 
targeting IncA was found to co-localize with the inclusion but did not induce aberrant morphology, 315 
which has been observed from microinjection of anti-IncA IgG, or neonatal Fc receptor (FcRn) 316 
delivery of IgG [21, 31]. Addition of anti-CPAF IgA showed diffuse staining consistent with negative 317 
controls (not shown). Taken together, these data demonstrate that IgA targeting extraepithelial 318 
chlamydial antigen (MOMP) prevents infection in a pIgR-dependent manner but  IgA targeting 319 
intraepithelial chlamydial antigens is unable to neutralize an established infection when targeting 320 
secreted protease CPAF or inclusion membrane protein IncA, despite colocalizing with the chlamydial 321 
inclusion.  322 
SIgA Specific for Extra but not Intraepithelial Chlamydial Antigens, Reduces Infection in vivo 323 
Unlike C. muridarum infection of female C57BL/6 mice which is generally resolved within 3-5 weeks 324 
[32], infected male C57BL/6 mice continued to have a viable infection in the testes, bladder and penis 325 
for at least 7 weeks (Figure 4A). To access the ability of vaccination to reduce infection, 3 weeks post-326 
infection was chosen as this was found experimentally to be the point where infection plateaued in 327 
mice. To determine if the in vitro results could be replicated in vivo, we initially attempted IP and 328 
systemic retro-orbital passive immunization of 0.2 mg of biotinylated purified IgA, and quantified the 329 
amount of IgA delivered to the bladder (in urine) and prostate (prostatic fluid). Passive immunization 330 
of mice supplied minimal concentrations of biotinylated IgA to the reproductive tract and this rapidly 331 
declined to the limit of detection by ELISA (<10 ng/mL) within 48 hours (Supplementary Figure 1A-B). 332 
To overcome the limitations observed from passive immunization, we followed the same immunization 333 
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schedule utilized to produce polyclonal IgA against MOMP and IncA for in vitro experiments, but 334 
depleted mice of CD4+ T cells prior to and throughout the infection to isolate the effects of antibodies 335 
(Figure 4B). Previous studies have also identified that live respiratory infection can provide some 336 
degree of protection against a genital challenge [33]; therefore, we included this group to determine if 337 
protection was mediated by SIgA/CD4+ T cells. There was no significant change in cachexia between 338 
WT and pIgR-/- mice following respiratory challenge suggesting a limited role for IgA in resolution of 339 
respiratory infection (Supplementary Figure 2A). Following 3 weeks of infection or immunization and 340 
23 days of CD4+ depletion, immunized and intranasally infected mice developed a robust Ag-specific 341 
IgA (Figure 4C) and IgG responses (Supplementary Figure 2B) and responses were equivalent 342 
between both WT and pIgR-/- mice. All groups receiving αCD4 treatment showed >95% depletion of 343 
CD3+CD4+ T cells in the spleen and draining lymph nodes (Supplementary Figure 2C-D).   344 
To determine the chlamydial burden across the urogenital tract, we measured infectious load in the 345 
testes (Figure 4D), bladder (Figure 4E), and penis (Figure 4F). MOMP-immunization of WT mice 346 
afforded a significant reduction in total chlamydial burden in the testes (73 %; P < 0.01), bladder (50 347 
%; P < 0.05) and penis (73 %; P < 0.01), relative to OVA-immunized controls. Importantly, the 348 
protection provided by MOMP immunization was entirely abrogated in pIgR-/- (and hence SIgA-/-) 349 
mice. Interestingly, prior intranasal infection and CD4-depletion of WT or pIgR-/- produced no 350 
significant protection suggesting a limited role of SIgA in immunity acquired from natural infection. WT 351 
and pIgR-/- mice immunized with IncA had significant reductions of infectious burden in the testes (73 352 
% in WT, 46% in pIgR-/-; P < 0.01) and bladder (50 % in WT, 41% in pIgR -/-; P < 0.05) when 353 
compared to control OVA-immunized mice suggesting protection observed was not dependent on 354 
SIgA. . Taken together, these findings suggest pIgR-mediated transport of IgA specific for MOMP 355 
provides significant protection in the male reproductive tract. Conversely, targeting intraepithelial 356 
antigen IncA with transcytosing IgA has little effect on reducing infectious burden.  357 
358 
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Discussion 359 
SIgA and the pIgR play pivotal roles in mucosal homeostasis and immunity [34]. During infectious 360 
challenge, the pIgR-mediated delivery of secretory component (non-specific innate defense) and 361 
more importantly SIgA to the mucosal lumen provides protection from tissue invasion. All Chlamydia 362 
spp. infect via the mucosa of either the ocular, respiratory, anorectal or urogenital tracts and thus 363 
come into direct contact with lumenal SIgA, but also potentially transcytosing dIgA during 364 
intraepithelial chlamydial replication. As pIgR is expressed in both the male and female lower 365 
reproductive tracts [35], it likely plays an important protective role in preventing initial infection, but 366 
also can prevent ascending infection to the gonads.  367 
To address the potential for antigen-specific IgA to interact with intra- and extra-epithelial chlamydiae, 368 
we established a method to purify dIgA from immunized pIgR-/- mice, and apply it to polarized 369 
epithelia in the presence or absence of murine pIgR. Apically delivered MOMP-SIgA afforded 24 % 370 
neutralization of 105 IFUs, and protection was dependent of transcytosis by pIgR. The rate of 371 
transcytosis in this model was calculated in mpIgR transfectants to be approximately 1 µg/cm2/day 372 
(equivalent to 0.35 µg/well or 1.75 µg/mL of polyclonal total IgA transcytosed into the apical 373 
compartment). Additionally, the concentration is lower than total polymeric IgA levels observed in 374 
rodent vaginal washes (5.29  ± 5.81 µg/mL) [36], and much lower than human vaginal fluid (21 - 118 375 
µg/mL), uterine cervical fluid (3 - 330 µg/mL) and ejaculate (11 - 23 µg/mL) [37]. This suggests that 376 
improving anti-MOMP IgA production in the reproductive tract via mucosal immunizations is an 377 
attractive target for future vaccine development. 378 
In MOMP-immunized mice the expression of pIgR, and thus transport of SIgA, significantly reduced 379 
chlamydial burden in the testes, bladder and penis. In the absence of pIgR (and CD4+ T cells) there 380 
was no protection, revealing a limited role for other antigen-specific effectors in the male genital tract 381 
(eg. IgG, CD8+). In fact, we have previously shown that the presence and transcytosis of anti-MOMP 382 
IgG provides no protection in the context of infectious burden or pathology [31, 38]. This inability of 383 
MOMP-IgG to neutralize EBs outside of defined in vitro conditions is due to Fc gamma receptor or 384 
FcRn-mediated uptake of IgG-opsonized EBs, and subsequent EB escape from lysosomal 385 
degradation [39]. Interestingly, despite minimal pIgR expression in the upper reproductive tract [35], 386 
we also observed a significant reduction in chlamydial infection in the testes of MOMP-immunized WT 387 
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mice, but not pIgR-/- mice suggesting SIgA is important in preventing ascending infection. Conversely 388 
in mice previously infected, there was no significant pIgR/SIgA mediated protection on secondary 389 
challenge, consistent with the knockout of IgA in previous studies [12]. Interestingly, in control groups 390 
(OVA immunized ± CD4-depletion) there was no significant protection in any tissues screened 391 
revealing the limited ability of CD4+ T cells to control infection in naïve males within the first three 392 
weeks. A limitation of this in vivo model is that pIgR also transports  pentameric IgM, however, the 393 
concentration of IgM in mucosal secretions is 10-100 fold lower than of IgA or IgG [37]. Together, this 394 
suggests that vaccines that induce SIgA targeting extraepithelial chlamydial antigens may significantly 395 
reduce infection in males and may also reduce the transmission of infection to females. 396 
Intra-epithelial IgA has been shown to neutralize internalized HIV and influenza viruses and the 397 
intracellular niche Chlamydia establishes during infections may also be vulnerable to trafficking IgA. 398 
We demonstrate that pIgR-dependent transcytosis of anti-IncA IgA is able to colocalize with the 399 
chlamydial inclusion yet does not significantly reduce infection in vitro. We demonstrated that IncA-400 
immunization conferred protection in vivo; however, this was not dependent on SIgA as there were 401 
negligible differences between infectious burden in WT and pIgR-/- mice. The in vivo reduction in 402 
burden afforded from IncA-immunization was likely due to intraepithelial IgG transported by FcRn, 403 
which we have previously demonstrated in vitro and in vivo [31]. Unlike intraepithelial IgA which can 404 
neutralize pathogens through recycling endosomes [18], intraepithelial IgG bound to antigen can 405 
mediate lysosomal degradation [40], as well as the recruitment of sequestomes providing a 406 
neutralizing mechanism beyond steric blocking [31].  Vaccines targeting other cytoplasmic-facing Incs 407 
(e.g. CT813 or CT229) may produce more promising results as they are expressed earlier during the 408 
infectious cycle and may have the potential to arrest chlamydial escape from the endocytic pathway. 409 
Intraepithelial IgA targeting other chlamydial antigens within the inclusion (proteins associated with 410 
the replicating RBs) is unlikely to neutralize as SIgA is a large heterodimeric protein (405 kDa) and 411 
the permeability of the inclusion membrane excludes molecules larger than 0.5 kDa [41]. IgA targeting 412 
the secreted protease CPAF provided no protection, consistent with other findings [42]. Targeting 413 
other inclusion-secreted chlamydial proteases; e.g. high temperature requirement A (HtrA) or tail-414 
specific protease (Tsp), with trafficking IgA may also provide little protection as these proteases are 415 
also secreted into the host cytoplasm but are unlikely to interact with the microtubule network 416 
unilaterally trafficking IgA. Recently, we have demonstrated that FcRn-mediated (bidirectional) 417 
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trafficking of IgG targeting CPAF also fails to neutralize infection and together with these data 418 
demonstrate that neither intraepithelial CPAF-IgA or IgG  is likely to play a significant role in reducing 419 
infectious burden.  420 
Taken together, we demonstrate the pIgR-mediated delivery of SIgA targeting extraepithelial 421 
chlamydial antigens significantly reduces infectious burden in vitro and in vivo whereas IgA targeting 422 
prominent intraepithelial chlamydial antigens provides no significant protection in vitro or in vivo. We 423 
confirm that in addition to IgG, transcytosing IgA can also interact with the inclusion revealing the 424 
potential to target chlamydial proteins necessary for growth, viability, nutrient acquisition, or escape 425 
from host endosomal degradation or antigen processing/presenting pathways. In the context of a 426 
male vaccine, SIgA targeting EB surface-exposed proteins are attractive vaccine candidates to 427 
reduce infectious burden throughout the reproductive tract, and will likely also reduce the transmission 428 
dose to sexual partners. The converse protection afforded from extraepithelial IgA but not IgG, and 429 
intraepithelial IgG but not IgA may explain why antibodies have such contradictory roles in many 430 
vaccine studies. These data reveal that SIgA targeting surface-exposed EB antigens is indeed 431 
important in protective chlamydial immunity, but also that intraepithelial binding of prominent 432 
chlamydial antigens IncA and CPAF by trafficking IgA provides no protection.  433 
434 
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Figure Legends: 558 
Figure 1: Purification of Antigen-Specific Dimeric Mouse IgA  559 
(A) Potential chlamydial antigen targets for intra and extra epithelial IgA. SDS-PAGE gels of purified 560 
recombinant C. muridarum antigens MOMP, IncA (B), and CPAF (C). (D) Serum from 561 
MOMP/IncA/CPAF or OVA-immunized mice was pooled (n =10), depleted of IgG and purified with 562 
Affiland® Mouse IgA Purification Resin. Samples were separated on SDS-PAGE, blocked and probed 563 
with anti-mouse IgA (alpha chain) HRP conjugated antibodies. (E) Non-reducing/non-denaturing SDS-564 
PAGE of IgA and IgG elutions. (F) Protein antigens were separated by SDS-PAGE, and western 565 
blotted with corresponding purified IgA. Bound IgA was detected with anti-mouse IgA (alpha heavy 566 
chain)-HRP IgG. 567 
Figure 2: A model to Evaluate Efficacy of Intra and Extraepithelial IgA against chlamydial 568 
infection 569 
Schematic showing in vitro model used to access intra and extraepithelial neutralization. (B) MDCK I-570 
II, HEC-1A, ECC-1, C2Bbe1, Vero E6 and BEAS-2b cells were grown on Transwell® inserts and the 571 
TEERs recorded. (C) Susceptibility of cell lines to apical infection following 5 days of polarization on 572 
Transwell® inserts. (D) Quantitative expression of human pIgR mRNA in BEAS2b, ECC-1, C2Bbe1, 573 
and HEC-1A cells was determined by qRT-PCR. (E) C2Bbe1 cells (+/- mpIgR) were fixed and 574 
incubated with pIgR-/- mouse sera, and bound IgA was detected with goat-anti mouse IgA-HRP 575 
antibody. (F-G) C2Bbe1 cells were grown on Transwell® inserts for 5 days then apically infected with 576 
C. muridarum for 24 h. (F) TEER of C2Bbe1 cells following 24h of infection. (G) Confocal microscopy 577 
demonstrating tight junction (ZO-1) expression in mock and C. muridarum-infected C2Bbe1 cells. (H) 578 
C2Bbe1 cells (+/- mpIgR) were grown on Transwell® inserts for 5 days and then purified mouse IgA 579 
was basolaterally loaded. Apical samples were taken and quantified by sandwich ELISA at 1, 3, 6 and 580 
24 h post inoculation. Errors bars represent mean +/- S.E.M (n=3-4). Scale = 25 µm. ND = none 581 
detected. 582 
Figure 3: The pIgR mediates delivery of neutralizing IgA to Extra but not Intraepithelial 583 
chlamydial antigens 584 
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C2Bbe1 cells (+/- mpIgR) were seeded on Transwell® inserts for 5 days. 100 µg of purified IgA was 585 
loaded basolaterally and allowed to transport for 24h. Cells were then apically infected with 105 IFUs 586 
of C. muridarum for 24h. Inclusion forming units were quantified by fluorescence microscopy. (A) 587 
Neutralization of chlamydial infection in polarized epithelia loaded basolaterally with polyclonal IgA 588 
from mice immunized with MOMP or OVA. (B) Neutralization of chlamydial infection in polarized 589 
epithelia loaded basolaterally with polyclonal IgA from mice immunized with IncA, CPAF or OVA. (C) 590 
Confocal microscopy of OVA and IncA-IgA treated cells staining for DNA (DAPI), Chlamydia (anti-591 
MOMP), and mouse IgA (IgA). Results representative of 3 individual experiments (n = 4 inserts per 592 
group). Error bars showing mean +/- S.E.M. Scale = 10 µm. 593 
Figure 4: SIgA targeting Extra but not Intraepithelial chlamydial antigen reduces burden in the 594 
MRT 595 
(A) Chlamydial burden in the male mouse testes, bladder and penis over 7 weeks was quantified by 596 
cell culture (n = 5 per time point). (B) Schematic representing immunization schedule, CD4 depletion 597 
and urogenital chlamydial challenge. (C) Antigen-specific serum IgA titers in WT and pIgR-/- mice 598 
following immunization were determined by ELISA with corresponding immunized antigen (IN Cmu 599 
mouse sera was screened using UV-inactivated EBs). Following 3 weeks of infection, chlamydial 600 
burden in the testes (D), bladder (E), and penis (F) of immunized mice was quantified by cell culture. 601 
Statistics determined by one way ANOVA. Error bars represent mean +/- S.E.M. 602 
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